Companies by category
A comprehensive landscape of BCI companies as of February 2026, covering invasive implants, non-invasive wearables, neuromodulation platforms, and enabling technologies. Organized by approach type, with estimated company size and stage of progress.
Market context: The global BCI market was valued at approximately $4 billion in 2024 and is projected to reach $10.9 billion by 2032, growing at ~14.6% CAGR. Neurotech venture funding hit an estimated $4.8 billion across 140 deals in 2025 alone.
Invasive / Implantable BCI
Companies developing electrode arrays, implants, or devices placed on or inside the brain.
| Company | HQ | Est. Size | Funding / Valuation | Stage of Progress |
|---|---|---|---|---|
| Neuralink | Fremont, CA, USA | 400–700 employees | >$1B raised; $650M Series E (Jun 2025); ~$9B valuation | Clinical trials. 12+ human implants as of early 2026. N1 chip (“Telepathy”) enables paralyzed users to control devices, browse web, play games. First UK trial began Jul 2025. |
| Synchron | New York, NY, USA | 100–200 employees | ~$200M+ raised; $200M Series D (Nov 2025) | Clinical trials. Stentrode endovascular BCI implanted via jugular vein (no open brain surgery). 10+ participants implanted. Expanded FDA approval (Dec 2025) for ALS. First native integration with iPhone, iPad, and Apple Vision Pro. |
| Paradromics | Austin, TX, USA | 50–100 employees | ~$123M raised ($105M VC + $18M NIH/DARPA grants) | Clinical trials. Connexus BCI completed first-in-human recording (Jun 2025). 1,600+ channel system with >200 bps information transfer rate. FDA-approved clinical study underway. Targets speech restoration for ALS/stroke. |
| Precision Neuroscience | New York, NY, USA | 100–150 employees | $102M Series C (Dec 2024); >$150M total | Clinical trials. Layer 7 Cortical Interface sits on brain surface (minimally invasive, reversible). Record-setting 4,096-electrode human recordings. Adopted by major US hospitals for real-time brain mapping (Feb 2026). Founded by Neuralink co-founder Benjamin Rapoport. |
| Blackrock Neurotech | Salt Lake City, UT, USA | 100–200 employees | >$200M raised | Clinical / pre-commercial. Utah Array is the most widely implanted BCI (30+ human implants). MoveAgain system has FDA Breakthrough Device designation. New DARPA defense-focused BCI partnership (Jan 2026). |
| INBRAIN Neuroelectronics | Barcelona, Spain | 50–100 employees | $68M+ raised; $50M Series B (Oct 2024) + €4M PERTE Chip grant (2025) | Clinical trials. World’s first graphene-based BCI. First human trial at Salford Royal Hospital (UK) in brain cancer patients. FDA Breakthrough Device Designation for Parkinson’s. Collaboration with Merck KGaA and imec for commercial scaling. |
| Science Corporation | Alameda, CA, USA | 50–100 employees | ~$177M raised; $104M financing (Apr 2025) led by Khosla Ventures | Late-stage clinical / pre-approval. PRIMA retinal BCI implant restored vision in 84% of patients (published in NEJM, Oct 2025). CE Mark application submitted; European launch anticipated 2026. FDA process underway. Founded by Max Hodak (former Neuralink president). |
| CorTec | Freiburg, Germany | 50–80 employees | Undisclosed (VC + grant-funded) | Clinical trials. BrainInterchange closed-loop BCI system: first human implant in Germany (Jul 2025) at UW Medicine/Harborview. FDA-approved clinical trial for stroke rehabilitation. First implantable BCI developer in Germany. |
| Motif Neurotech | Houston, TX, USA | 30–50 employees | >$30M VC + non-dilutive (DARPA, NIH, ARIA UK) | Pre-clinical / early clinical. DOT: blueberry-sized implantable brain stimulator for treatment-resistant depression. 20-minute outpatient procedure. Patient registry launched (Dec 2025). Clinical trials expected H1 2026. Rice University spinout. |
| NeuroPace | Mountain View, CA, USA | ~170 employees | $248M total funding; publicly traded (NPCE); ~$72M revenue | Commercial. RNS System is FDA-approved, commercially available responsive neurostimulation for drug-resistant epilepsy. Only closed-loop neurostimulation device on market for epilepsy. |
| ONWARD Medical | Eindhoven, Netherlands | 100–150 employees | Publicly traded (Euronext: ONWD) | Clinical trials / early commercial. ARC-IM and ARC-EX spinal cord stimulation systems form a “digital bridge” to restore movement after spinal cord injury. Featured on 60 Minutes. CE Mark for ARC-EX. |
| Axoft | Cambridge, MA, USA | 10–30 employees | Early-stage (incl. Stanford license deal, 2025) | Pre-clinical. Develops ultra-soft, flexible neural implant material (Fleuron) designed to match brain tissue compliance. Material now commercially available for research. Focused on biocompatibility for long-term implants. |
| ABILITY Neurotech | Geneva, Switzerland | 20–40 employees | Early-stage (Wyss Center spinoff, Jan 2025) | Pre-clinical. Europe’s first fully implantable BCI company. Spun out of Wyss Center after 8 years of R&D under BCI pioneer John Donoghue. Targets ALS, stroke, spinal cord injury. |
| Braingrade | USA | 10–20 employees | Early-stage | Pre-clinical / R&D. Developing BCIs targeted at Alzheimer’s disease applications. |
| Diagnostic Biochips | Glen Burnie, MD, USA | 10–20 employees | ~$6M (NIH + DARPA); $500K MSCRF award | Pre-clinical. Microfabricated implantable neurosensor platform with high spatiotemporal resolution brain data. |
Endovascular / Semi-Invasive / Minimally Invasive BCI
| Company | HQ | Est. Size | Funding / Valuation | Stage of Progress |
|---|---|---|---|---|
| Merge Labs | Los Angeles, CA, USA | 20–50 employees (hiring) | $252M seed; $850M valuation (Jan 2026) | Early R&D / stealth. Co-founded by Sam Altman. Ultrasound + molecular approach to non-implantable BCI. OpenAI lead investor. Spinoff of Forest Neurotech nonprofit. Targeting chronic pain, stroke, depression. |
| Forest Neurotech | Los Angeles, CA, USA | 20–40 employees | Philanthropic (Convergent Research / Schmidt Futures); $20M Butterfly Network partnership | R&D. Nonprofit Focused Research Organization pioneering ultrasound BCIs. Forest 1 device: miniaturized ultrasound scanner for brain imaging and neuromodulation. Early-stage safety trial in UK. |
Non-Invasive BCI — Consumer / Wearable
Companies building EEG, fNIRS, or other external sensor-based BCIs for consumer, wellness, or productivity use.
| Company | HQ | Est. Size | Funding / Valuation | Stage of Progress |
|---|---|---|---|---|
| Neurable | Boston, MA, USA | 30–60 employees | $65M total; $35M Series A (Dec 2025) | Commercial. EEG-based BCI embedded in consumer headphones. MW75 Neuro and MW75 Neuro LT (with Master & Dynamic). Neurable AI platform tracks focus, fatigue, cognitive load. Expanding into gaming/esports. US Air Force research partnership. |
| Emotiv | San Francisco, CA, USA | 50–100 employees | ~$25M+ raised | Commercial. EPOC, Insight, and MN8 EEG earbuds (2024). Wireless EEG headsets used across research, workplace wellness, gaming, defense. EmotivBCI software suite. 2025 strategic stake in MEG-startup MYndspan. |
| InteraXon (Muse) | Toronto, Canada | 50–80 employees | ~$30M+ raised (incl. $9.5M Series C, 2022) | Commercial. Muse S Athena (Mar 2025): first consumer headband combining EEG + fNIRS. Over 500,000 users. 1 billion+ minutes of brain data. Used by NASA for astronaut training. FDA clearance for medical settings. |
| OpenBCI | Brooklyn, NY, USA | 20–40 employees | Undisclosed (crowdfunded + VC) | Commercial. Open-source EEG hardware + software. Galea Neon (Nov 2025, with Pupil Labs): wireless all-in-one brain, body, and eye-tracking headset for XR research. |
| BrainCo | Somerville, MA / Hangzhou, China | 100–200 employees | ~$287M raised (2B yuan round, 2025); ~$1.3B valuation; IPO preparation | Commercial / scaling. Non-invasive EEG products: FocusCalm headband, BrainRobotics prosthetics, NeuroMaker STEM kits. Targets autism, ADHD, Alzheimer’s, insomnia. Harvard spinout. Filed for Hong Kong IPO. |
| Kernel | Los Angeles, CA, USA | 50–100 employees | >$100M raised | R&D / pilot. Kernel Flow: wearable fNIRS helmet for non-invasive brain imaging. Measures cerebral blood flow and cognitive function. Piloting with academic and clinical institutions. Founded by Bryan Johnson. |
| NeuroSky | San Jose, CA, USA | 30–50 employees | Undisclosed | Commercial. EEG biosensor chips and headsets. ThinkGear ASIC module widely embedded in consumer and OEM products (toys, education, wellness). One of earliest consumer EEG companies (est. 2004). |
| Cognixion | Santa Barbara, CA, USA | 20–40 employees | ~$12M seed (2021); led by Prime Movers Lab | Pre-commercial. Cognixion ONE: non-invasive BCI + AR headset for communication disabilities (ALS, cerebral palsy). Axon-R platform now distributed by Blackrock Neurotech (2025). Amazon Alexa integration. |
| Arctop | Los Angeles, CA, USA | 20–40 employees | Undisclosed (VC-backed) | Commercial. Software platform using AI to decode brain activity in real time from any EEG hardware. APIs for cognition, emotion, and intent. Hardware-agnostic. |
| LumiMind | USA / China | 20–40 employees | Undisclosed | Pre-commercial. Debuted at CES 2026: LumiSleep closed-loop EEG sleep headband with on-device processing. Claims non-invasive control comparable to implanted systems. |
| Neeuro | Singapore | 20–40 employees | Undisclosed | Commercial. EEG headband (SenzeBand) + gamified brain training platform. Focus on ADHD, cognitive assessment, education. Active in Asia-Pacific BCI digital therapeutics market. |
| Sens.ai | USA | 10–20 employees | Undisclosed | Commercial. Consumer headset combining EEG, HRV, and photobiomodulation (PBM). Personalized neurofeedback programs for cognitive health and performance. |
| Neurosity | New York, NY, USA | 10–20 employees | Undisclosed | Commercial. Crown: developer-focused EEG headset. Raw EEG data + productivity metrics. SDK for building BCI applications. |
| FocusBand | Australia | <10 employees | Undisclosed | Commercial. Consumer EEG headband for sports performance, mindfulness, and focus training. Used in golf and baseball performance coaching. |
| BrainBit | USA / Russia | 10–30 employees | ~$10M raised | Commercial. Compact consumer EEG headband for meditation, neurofeedback, and sleep. Focus on affordability and wearability. |
| Mendi | Stockholm, Sweden | 10–30 employees | Undisclosed | Commercial. fNIRS-based neurofeedback headband for brain training. Visual feedback via app. Consumer-oriented, targeting cognitive performance and well-being. |
| NextSense | Mountain View, CA, USA | 20–40 employees | $16M Series A (2025) | Pre-commercial. “Brain-responsive” earbuds (Tone) using EEG for adaptive audio sleep therapy. Google spinout. |
| IDUN Technologies | Zurich, Switzerland | 10–20 employees | Undisclosed (grant + VC) | Pre-commercial. Dry-electrode EEG earbuds for everyday brain monitoring. B2B focus on OEM integration into hearables. ETH Zurich spinout. |
| Wisear | Paris, France | 10–20 employees | Undisclosed | Pre-commercial. Neural interface integrated into earbuds and glasses. Uses EEG + EMG for hands-free device control. Partnering with consumer electronics OEMs. |
| EarSwitch | UK | <10 employees | Early-stage | R&D. In-ear neural interface using voluntary middle-ear muscle contractions for hands-free control. Novel non-EEG approach. |
| Kokoon | London, UK | 10–20 employees | Undisclosed | Commercial. EEG-enabled sleep headphones that track sleep stages and adapt audio in real time. Consumer wellness focus. |
Non-Invasive BCI — Medical / Clinical
Companies focused on clinical-grade non-invasive neural interfaces for diagnosis, rehabilitation, or treatment.
| Company | HQ | Est. Size | Funding / Valuation | Stage of Progress |
|---|---|---|---|---|
| g.tec medical engineering | Schiedlberg, Austria | 100–250 employees | Self-funded / profitable (est. 1999) | Commercial. Leading medical BCI manufacturer. recoveriX: closed-loop motor rehabilitation (stroke, MS, Parkinson’s). mindBEAGLE: assessment for disorders of consciousness. FDA and CE approved systems. Deployed globally in hospitals and rehab clinics. |
| Ceribell | Mountain View, CA, USA | 100–200 employees | $207M (IPO); VC-backed prior | Commercial (public). AI-powered point-of-care EEG system with Clarity algorithm for seizure detection. FDA-cleared for ages 1+. FedRAMP High authorization. Rapid deployment EEG for acute care. |
| MindMaze | Lausanne, Switzerland | 100–200 employees | >$300M raised; previously valued at >$1B (unicorn) | Commercial. MindMotion PRO: VR + BCI neurorehabilitation for stroke and TBI. FDA and CE approved. Used in hospitals across US and Europe. |
| BrainQ (BRAIN.Q) | Jerusalem, Israel | 30–60 employees | ~$50M+ raised | Clinical trials. AI-powered electromagnetic stimulation therapy for stroke recovery. EMAGINE pivotal trial underway. FDA Breakthrough Device Designation. WEF Technology Pioneer. Wearable helmet for clinic and home use. |
| Cala Health | San Mateo, CA, USA | 50–100 employees | >$250M raised (GV, Lux Capital, J&J, Novartis Ventures) | Commercial. Cala kIQ: FDA-cleared wrist-worn neuromodulation for essential tremor. Individualized peripheral nerve stimulation. Expanding into cardiology and psychiatry. |
| Omniscient Neurotechnology (o8t) | Sydney, Australia | 30–60 employees | AUD $40M Series B (2021); $20M from Australia NRF for Series D (2025) | Commercial. Quicktome: FDA-cleared digital brain mapping platform using connectomics for neurosurgical planning. AI-powered brain network analysis from MRI. |
| Bitbrain | Zaragoza, Spain | 20–40 employees | Undisclosed | Commercial. B2B neurotechnology platform: EEG hardware + AI software for research, neuromarketing, and cognitive assessment. University of Zaragoza spinout. |
| Compumedics | Melbourne, Australia | 100–200 employees | Publicly traded (ASX: CMP) | Commercial. Clinical EEG/PSG systems for sleep and brain monitoring. Grael HD-EEG platform. Long-established player in neurodiagnostics (est. 1987). |
| Nihon Kohden | Tokyo, Japan | 5,000+ employees | Publicly traded (TYO: 6849) | Commercial. Major medical device corporation producing clinical EEG systems. Global presence in neurology diagnostics. |
| ANT Neuro | Hengelo, Netherlands | 50–100 employees | Part of Eemagine group | Commercial. Medical-grade EEG amplifiers and electrode systems (eego, waveguard). Focus on clinical EEG, source localization, and BCI research. |
| Brain Products | Gilching, Germany | 50–100 employees | Privately held | Commercial. Research-grade EEG amplifiers and recording systems (actiCHamp, LiveAmp). Widely used in academic BCI research worldwide. |
| Neuromod Devices | Dublin, Ireland | 50–80 employees | ~€10M+ equity round (2025) | Commercial. Lenire: bi-modal neuromodulation device for tinnitus. 91.5% clinically meaningful improvement (Nature Communications Medicine). MDSAP and EU MDR certified. Scaling US and EU rollout. |
| Omind Neurotechnologies | Paris, France | 10–30 employees | $23M Series D | Commercial. Brain training platform for mental performance and mental health. Collaborations with IRBA, CNRS, AP-HP. |
| Neuronic | USA | 10–20 employees | Undisclosed | Pre-commercial. Neuronic LIGHT: transcranial photobiomodulation (tPBM) helmet for memory, movement, mood. Near-infrared light therapy with app connectivity. |
| Openwater | San Francisco, CA, USA | 20–40 employees | $100M total funding (Aug 2024); Khosla Ventures, BOLD Capital | R&D / pre-clinical. Non-invasive brain imaging and modulation using holographic principles and infrared light. Working toward portable, real-time neural imaging. |
| Cerca Magnetics | Nottingham, UK | 20–40 employees | Undisclosed (University of Nottingham spinout) | Pre-commercial. Wearable magnetoencephalography (MEG) using optically pumped magnetometers (OPMs). Room-temperature MEG system enabling brain imaging during movement. |
Chinese BCI Companies
China has announced a national BCI roadmap (Aug 2025) targeting major milestones by 2027 and a full supply chain by 2030, backed by an 11.6 billion yuan ($165M) brain science fund.
| Company | HQ | Est. Size | Funding / Stage |
|---|---|---|---|
| BrainCo 强脑科技 | Hangzhou / Somerville, MA | 100–200 employees | $287M raised; ~$1.3B valuation; IPO preparation |
| NeuroXess 脑虎科技 | Shanghai | 50–100 employees | ”Several hundred million” yuan; implantable flexible BCI; first clinical trial for Chinese language synthesis (Dec 2024) |
| Neuracle 博睿康 | Beijing | 50–100 employees | Multiple rounds; non-invasive and semi-invasive BCI platforms for research and clinical use |
| NeuralMatrix 宁矩科技 | China | 20–50 employees | VC-backed; developing BCI chips and neural interface systems |
| StairMed Technology 阶梯医疗 | Shanghai | 30–60 employees | $48M Series B (Feb 2025); BCI for neurological rehabilitation |
| Gestala | China | 10–20 employees (Jan 2026 launch) | Angel round in progress; non-invasive ultrasound BCI for chronic pain, stroke, depression; first product expected Q3 2026 |
| Beijing Xinzhida Neurotechnology | Beijing | 50–100 employees | Government + VC; implantable neural interfaces for stroke rehabilitation and motor dysfunction |
| Bo Rui Kang Tech | China | Undisclosed | BCI for rehabilitation and assistive technology |
| Aoyi Tech | China | Undisclosed | BCI for rehabilitation and assistive technology |
| Brainland Tech | China | Undisclosed | BCI for rehabilitation applications |
| Zhiran Medical | China | Undisclosed | BCI for medical rehabilitation |
| Flexolink 柔灵科技 | China | Undisclosed | Flexible BCI electrodes and systems |
| Yunrui Intelligence 云睿智能 | China | Undisclosed | BCI for consumer and clinical applications |
| ZhenTai Intelligence 臻泰智能 | China | Undisclosed | BCI for rehabilitation |
| ECon 念通智能 | China | Undisclosed | BCI for communication and assistive tech |
| BrainUp 脑陆科技 | China | Undisclosed | Non-invasive consumer BCI |
Neuromodulation & Adjacent BCI
Companies in deep brain stimulation, spinal cord stimulation, and vagus nerve stimulation whose platforms include neural interface / BCI components.
| Company | HQ | Est. Size | Stage |
|---|---|---|---|
| Medtronic (Neuromodulation) | Dublin, Ireland / Minneapolis, USA | 100,000+ employees (company-wide) | Commercial. Largest neuromodulation company globally. DBS systems with brain sensing (SenSight, Percept PC). ~20% of invasive BCI-adjacent market share. |
| Abbott (Neuromodulation) | Chicago, IL, USA | 110,000+ employees (company-wide) | Commercial. DBS and spinal cord stimulation systems. |
| Boston Scientific (Neuromodulation) | Marlborough, MA, USA | 45,000+ employees (company-wide) | Commercial. Vercise DBS systems for Parkinson’s. Neuromodulation for chronic pain. |
| BrainsWay | Jerusalem, Israel | 100–200 employees | Commercial (public). Deep TMS (transcranial magnetic stimulation) systems. FDA-cleared for OCD, MDD, smoking cessation. |
| LivaNova | London, UK | 3,000+ employees | Commercial (public). VNS Therapy for drug-resistant epilepsy and treatment-resistant depression. Submitting nerve stim for sleep apnea to FDA (2025). |
BCI Software, Platforms & Enabling Technology
| Company | HQ | Est. Size | Stage |
|---|---|---|---|
| Nimbus (Piramidal AI) | London, UK / YC-backed | 10–20 employees | Pre-commercial. Foundation model for brain signals. Bayesian decoders, continuous calibration. Building a “GPT for the brain” across BCI hardware. |
| Naox Technologies | Belgium | 10–20 employees | Pre-commercial. AI-driven EEG analysis software for clinical BCI applications. |
| NeuroFusion | USA | <10 employees | Pre-commercial. Open-source neural data platform for BCI research. |
| Artinis Medical Systems | Elst, Netherlands | 20–50 employees | Commercial. fNIRS hardware and software systems for brain research. |
| Datwyler (SoftPulse) | Switzerland | 8,000+ employees (group) | Commercial. SoftPulse dry electrodes for wearable EEG applications. Strategic partnership with BIOPAC (2025). |
| uCat | Asia | 10–20 employees | Pre-commercial. Emerging BCI hardware/software platform. |
| Wearable Devices Ltd. | Yokneam, Israel | 10–30 employees | Pre-commercial. Mudra Band: neural input wristband using surface nerve activity for gesture control. Apple Watch integration. |
| MYndspan | UK | 10–20 employees | Pre-commercial. MEG-based brain imaging startup. Emotiv strategic investment (2025). |
Key Metrics Summary
| Category | Count | Notable Trend |
|---|---|---|
| Invasive / implantable BCI | ~13 companies | At least 5 now in human clinical trials (Neuralink, Synchron, Paradromics, Precision, CorTec). Race to FDA approval intensifying. |
| Semi-invasive / ultrasound BCI | ~2 companies | Merge Labs’ $252M seed is one of the largest in BCI history. Ultrasound approaches gaining traction as non-surgical alternative. |
| Non-invasive consumer | ~17 companies | EEG headphones/earbuds becoming mainstream form factor. fNIRS emerging as complement to EEG. |
| Non-invasive clinical | ~14 companies | g.tec and Ceribell lead in deployed clinical BCI. Stroke rehabilitation and seizure detection are primary use cases. |
| Chinese BCI companies | ~16 companies | National BCI roadmap + $165M brain science fund. BrainCo’s $287M raise is second-largest globally after Neuralink. Over 50 clinical trials completed by mid-2025. |
| Neuromodulation majors | ~5 companies | Medtronic and Abbott dominate the invasive neuromodulation market. DBS systems increasingly incorporating neural sensing/BCI features. |
| Software / enabling tech | ~8 companies | Foundation models for brain data emerging (Piramidal AI). Open-source tools (OpenBCI, NeuroFusion) lowering barriers. |
| Total | ~75 companies |
Sources
- Spherical Insights — Top 10 BCI Companies 2025
- BiopharmaTrend — Merge Labs $252M Seed
- TechCrunch — China’s BCI Industry Racing Ahead (Feb 2026)
- BiopharmaTrend — 12 Emerging Neurotech Companies
- BiopharmaTrend — 10 Companies Shaping BCI Landscape
- Paradromics — Companies Like Neuralink
- Forbes — LumiMind at CES 2026
- ABILITY Neurotech — About
- LinkedIn — Feb 2026 Neurotech Roundup
- Science Corporation — PRIMA NEJM Results
- INBRAIN — $50M Series B
- Motif Neurotech — Patient Registry Launch
- Athletech News — Neurable $35M Series A
- Ross Dawson — Leading BCI Companies
- IntuitionLabs — Bay Area Neuroscience Companies
- China Briefing — China BCI Industry
- Neeuro — China’s Bold Push into BCI
- IDTechEx — Brain Computer Interfaces 2025-2045 Report
- ensun — Top 100 BCI Companies 2026
- CorTec — First Human BCI Implant Made in Germany
- Ellty — BCI Investors 2026
- NeuroTech Futures — Notables #31
- Verified Market Research via Yahoo Finance — BCI Market 2026-2032
- EIN Presswire / DataM Intelligence — BCI Market 2026-2034
- Wikipedia — Muse (headband)
Last updated: February 25, 2026